Unraveling the Maltese Melanoma Mystery

In the heart of Malta, at the bustling St. Julian’s promenade, you’ll find locals and tourists alike soaking up the Mediterranean sun. But for some Maltese families, the joy of sunbathing is tinged with worry. They’re part of a cluster of families affected by a rare, aggressive form of skin cancer, melanoma, linked to a unique genetic mutation.

Malta’s Melanoma Enigma

Malta, with its sunny climate and fair-skinned population, has one of the highest melanoma rates in Europe. But what sets Malta apart is a genetic mutation, dubbed ‘Maltese melanoma mutation,’ found in a significant number of local melanoma patients. This mutation, in the CDKN2A gene, is more aggressive and resistant to treatment than other melanoma mutations.

Dr. Maria Galea, a Maltese oncologist at Mater Dei Hospital, has been studying this mutation for years. “We first noticed it in the late 90s,” she says. “It’s not just more common here than elsewhere, it’s different. It’s more aggressive, and it affects younger people.”

Unraveling the Genetic Code

The CDKN2A gene is a tumor suppressor, meaning it helps stop cells from growing and dividing too rapidly. But when mutated, it can’t do its job properly, leading to uncontrolled cell growth and, potentially, cancer. The ‘Maltese melanoma mutation’ is a specific change in the gene’s code, unique to Malta.

Dr. Gordon Zarb, a geneticist at the University of Malta, is working to understand why this mutation is so prevalent in Malta. “It’s likely due to a founder effect,” he explains. “A common ancestor carried this mutation, and it’s been passed down through generations. With intermarriage common in Malta, the mutation has spread widely.”

Living with the Shadow of Melanoma

For families like the Abela family from Birkirkara, the mutation is a constant worry. They’ve lost several relatives to melanoma and have multiple family members living with the disease. “It’s always in the back of our minds,” says Maria Abela. “We’re careful in the sun, but we know we’re at higher risk.”

Early detection is key for melanoma. The Abela family has regular skin checks, and Maria is now advocating for more awareness and better access to genetic testing. “If we can catch it early, we have a better chance,” she says.

: Hope on the Horizon

Research is ongoing, both locally and internationally, to understand and combat this mutation. Dr. Galea is optimistic. “We’re learning more every day,” she says. “With better understanding, we can develop targeted treatments. It’s a slow process, but we’re making progress.”

For Maria Abela, hope lies in awareness and early detection. “We can’t change our genes, but we can change how we live with them,” she says. “Let’s make sure everyone knows the risk and gets checked early.”